



The Essential Elements of a Risk Governance Framework for Current and Future Nanotechnologies

Journal:	<i>Risk Analysis</i>
Manuscript ID	RA-00123-2017.R2
Wiley - Manuscript type:	Perspective
Key Words:	Risk communication, Nano-regulation, Risk governance

SCHOLARONE™
Manuscripts

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**The Essential Elements of a Risk Governance Framework
for Current and Future Nanotechnologies**

2nd revision submitted for publication in Risk Analysis

For Peer Review

Abstract

Societies worldwide are investing considerable resources into the safe development and use of nanomaterials. Whilst each of these protective efforts are crucial for governing the risks of nanomaterials, they are insufficient in isolation. What is missing is a more integrative governance approach that goes beyond legislation. Development of this approach must be evidence-based and involve key stakeholders to ensure acceptance by end users. The challenge is to develop a framework that coordinates the variety of actors involved in nanotechnology and civil society to facilitate consideration of the complex issues that occur in this rapidly evolving research and development area. Here, we propose three sets of essential elements required to generate an effective risk governance framework for nanomaterials:

1. Advanced tools to facilitate risk-based decision-making, including an assessment of the needs of users regarding risk assessment, mitigation and transfer. 2. An integrated model of predicted human behavior and decision-making concerning nanomaterial risks. 3. Legal and other (nano-specific and general) regulatory requirements to ensure compliance and to stimulate proactive approaches to safety. The implementation of such an approach should facilitate and motivate good practice for the various stakeholders to allow the safe and sustainable future development of nanotechnology.

Keywords: Decision-making; Nano-regulation; Risk communication; Risk governance; Risk management

1. INTRODUCTION

For over a decade it has been recognized that nanotechnologies offer great opportunities for society, but for them to reach their full potential the risks, particularly of nanomaterials (NMs), must be addressed.⁽¹⁾ An ever-expanding heterogeneous array of NMs are being incorporated into a diverse range of industries and applications. This variety and wide-spread use has fostered a growing interest in their safety and risk management. Thus, key stakeholders worldwide invest considerable resources into the safe development and use of NMs. More specifically, governments, private companies, and other actors have sought to govern human behaviors and decisions related to NMs through the use of various tools and risk management efforts. For example, internationally much effort has been directed to support risk assessment/management related research which will both help companies implement risk prevention (and mitigation) strategies, as well as aid the development of general and specific NM-relevant regulations.⁽²⁾ This work has included expert bodies (e.g. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)), regulators (e.g. European Food Safety Authority (EFSA) or the US Food and Drug Administration (FDA) and Environmental Protection Agency (EPA)), as well as academic researchers who have investigated whether existing risk assessment procedures and frameworks for conventional chemicals are applicable to NMs. In particular, these studies and reports have investigated and identified specific challenges for NMs risk assessment.^(3,4) This work has been complimented by efforts aimed at fostering dialogue with civil society and the general public in order to explore risks and advantages (risk communication), and with workers to facilitate a better understanding of risks, thereby aiming to stimulate more competent decisions and risk-reducing behavioral changes.

To align these substantial efforts, a comprehensive evidence-based, optimized, and transparent risk governance framework, specifically targeted at NMs, is now needed. Against the broad range of governance definitions in the literature,⁽⁵⁾ we understand governance as the

1
2
3 social and institutional arrangements that systematically influence patterns of behavior. These
4
5 include formal regulations, informal norms of appropriateness and established practical
6
7 routines.
8

9
10 A coherent NM risk governance framework should address the manifold challenges
11
12 that NMs pose to be addressed in a joined-up, coordinated manner, thereby avoiding piece-
13
14 meal solutions to NM risk management. It would support the governance of complex and
15
16 consequential risks in the presence of the specific challenges and uncertainty implied by many
17
18 NMs.⁽⁶⁾
19

20
21 Such a governance framework needs to be relevant to risk-related behaviors and
22
23 decisions by societal actors throughout the life-cycle of a given NM, whether they are pristine
24
25 materials or incorporated into a product. It would structure decision making and influence
26
27 behaviours at the institutional and individual level, allowing identification of the options
28
29 available to the various actors while understanding constraints such as who is entitled or
30
31 required to make a decision, who is responsible and who is liable.⁽⁷⁻⁹⁾ Decisions related to
32
33 NM risks are made within a context of both hard law (formal regulations and statutes), soft
34
35 law (non-binding agreements and established good practice) and non-legal social norms and
36
37 expectations (e.g. public blaming and shaming, reputational risks).
38
39

40
41 In this paper, we address these issues by drawing upon social sciences, material
42
43 science, legal-regulatory science, and risk-related research⁽¹⁰⁾ to identify and describe
44
45 essential elements of a risk governance framework for NMs. Moreover, we provide an outline
46
47 of the tools needed for such a framework, and how they could be integrated effectively.
48
49 Finally, we highlight the key factors required for the success of such an integrated risk
50
51 governance framework. We believe that the proposed framework provides a basis for a
52
53 comprehensive management of NM-related risks that will help to specify the needs for tool
54
55 development to facilitate risk decision making and thus to foster trust in NM innovation.
56
57
58
59
60

2. THE NEED FOR A SPECIFIC NANO-RISK FRAMEWORK

Currently the legal or regulatory requirements for nanotechnologies are spread over a fragmented set of regulations that cover general substances (e.g. Registration Evaluation Authorisation and Restriction of Chemicals (REACH), Toxic Substances Control Act (TSCA)), specific goods containing NMs (e.g. food law, chemical law, cosmetics law or pharmaceutical law), or aim to protect specific groups exposed to NMs (e.g. occupational health and safety regulation). A recent research roadmap by the European NanoSafety Cluster summarizes the current status of such regulations in Europe and the USA⁽¹¹⁾ and includes a number of general, non-nano-specific legal or regulatory procedures and frameworks that are applicable to nano-relevant risks.⁽¹²⁻¹⁴⁾ With respect to REACH, a number of dedicated studies (e.g. RIPON) and a REACH Review in 2012⁽¹⁵⁾ have assessed the suitability of this legislation,^(16,17) leading to a Commission Communication⁽¹⁸⁾ concluding that NMs “are covered by the definition of a “substance” in REACH, even though there is no explicit reference to nanomaterials.” According to the European Commission, REACH is hence applicable to NMs, making such materials subject to general registration with ECHA. However, legally this interpretation is not yet binding; final clarification would only be provided through an amendment of REACH or a judgment by the Court of Justice of the European Union (CJEU). Likewise, the US FDA reviews risk concerns of NMs within the context of the specific legal standards applicable to each type of product under its jurisdiction, such as with cosmetics, food additives, etc. This product-focused regulatory assessment empowers the FDA to conduct pre- and post-market reviews, and to coordinate with established domestic and international counterparts via the Emerging Technologies Interagency Policy Coordination Committee.

This suggests that the governance of risks related to NMs should be considered within the context of existing regulatory and legal frameworks. However, although the current procedures for risk assessment of conventional chemicals may, in principle, be applicable to

1
2
3 NMs,^(3,4) much effort has been made to improve this process, not only to ensure that it is NM-
4
5 relevant, but also with the future ambition to make the process more efficient and intelligent
6
7 in order to deal with the ever expanding number of NMs (and nano-enabled products). Yet,
8
9 current and future NMs pose a set of specific challenges for risk governance, which may
10
11 require a nano-specific risk governance framework.⁽⁶⁾ This demand is driven by multiple
12
13 economic and regulatory factors, including the rapid pace of commercial or near-market
14
15 development of NMs on a global scale. A nano-specific framework could harmonize risk-
16
17 based approaches for NM assessment for actors with traditionally diverging risk assessment
18
19 practices, and help indicate and ameliorate gaps in NM hazard, exposure, or effects
20
21 assessment that currently drive the field's uncertainty with regard to health risks. Without
22
23 such a nano-specific framework, it will be difficult for regulators and industry to resolve
24
25 uncertainties posed by NMs and their unique physical characteristics.
26
27
28

29
30 The cross-border flow of information and the internationalization of markets
31
32 necessitate the development of an international paradigm. The different regulatory regimes, in
33
34 particular different attitudes towards the precautionary principle, suggest that a multi-
35
36 stakeholder approach that leverages the development of NM best practices through the
37
38 coordination of effort by industry, government, and other relevant parties, could be most
39
40 promising in developing shared practice that fit the various regulatory environments.
41
42

43
44 One of the fundamental challenges for risk governance of NMs is that NMs often
45
46 share few common characteristics besides the nanoscale, and that they can exhibit multiple
47
48 forms and variations over their life-cycles.⁽¹⁹⁾ For example, NMs may undergo changes in
49
50 their physicochemical characteristics, such as agglomeration or de-agglomeration, in certain
51
52 environmental conditions, and this change may have an impact on the toxicity of the
53
54 respective NM.⁽⁶⁾ This challenge is further compounded by difficulties in identifying,
55
56 quantifying and discriminating between natural and engineered NMs.⁽⁶⁾ Not surprisingly, this
57
58 poses problems for the characterization of properties in toxicological studies, which may lead
59
60

1
2
3 to diversity in the applied methods and therefore difficulties in comparing findings.⁽²⁰⁾

4
5 Consequently, any framework for governing NM risks needs to pay attention to this specific
6
7 challenge and foster a viable way for risk assessment, notably for next-generation NMs, that
8
9 efficiently considers potential changes in the physicochemical characteristics of NMs during
10
11 their life cycles and the likely use of incomplete datasets.
12

13
14 Even for a seemingly “simple” question of the risk assessment process, NMs pose
15
16 particular challenges in comparison to conventional chemicals: no agreement so far has been
17
18 reached on a concept of dose, concentration or metric of NMs in test systems.⁽⁶⁾ This renders
19
20 the application of current risk assessment practices difficult.
21

22
23 As well as complying with existing regulatory and legal frameworks, any risk
24
25 assessment framework needs to be sufficiently flexible or adaptable to align with new
26
27 regulations as they adapt and evolve. Examples of this include considerations of
28
29 environmental, occupational, and food/drug-based regulatory requirements and oversight
30
31 driven within the US by the EPA, the Occupational Safety and Health Administration
32
33 (OSHA), and FDA,^(13,21,22) or in Europe by the European Environment Agency, EU-OSHA or
34
35 the EFSA.
36

37
38 Above we have addressed challenges relating to risk related research, material science
39
40 and the legal-regulatory environment, but in addition a governance framework will benefit
41
42 from integrating perspectives from other domains, in particular social sciences⁽¹⁰⁾ in order to
43
44 develop practical solutions for the important, urgent and complex risk decisions⁽²³⁾ regarding
45
46 NMs at all societal levels. Such a risk governance framework would significantly contribute
47
48 to the goal of achieving sustainable development for nanotechnologies. Furthermore it could
49
50 act as a model on which to build governance frameworks for other key emerging technologies
51
52 (KETs). Therefore, in order to spur discussion about such a comprehensive NM risk
53
54 governance framework and to suggest some key features and tools, we proffer a tentative
55
56 version of such a framework in the following.
57
58
59
60

3. A FRAMEWORK FOR NM RISK GOVERNANCE

3.1. The Essential Elements of the NM Risk Governance Framework

We propose that to construct an effective risk governance framework for NMs, three element groups are required (see Figure 1):

1. A set of *advanced tools and strategies to support risk decision making*. These start with assessment of the needs of the users (where do they work, what experience do they have in risk decision making, etc.) in order to ensure that the information provided is appropriate in content, style and level of detail.⁽²⁴⁾ This assessment of user needs will be linked to tools for risk assessment (spanning hazard, exposure and physicochemical characterization), mitigation (e.g. prevention of exposure, or reduced hazard using Safer by Design approaches) and transfer (e.g. insurance), which all feed into a tool for risk decision making.⁽²⁵⁾ The tools and strategies, which address potential risks posed by NMs along their value chain/life cycle, are currently both experimental and computational (see Table I, and Figure 1, central multi-colored circle). In line with ITS-NANO,⁽²⁶⁾ we propose that the reliance on testing should decrease over time as computational models become more comprehensive and robust.
2. An integrated model of *human behavior and decision making* (based on empirical data gathered at the individual, organizational, national and international level) that influences how the framework is refined, used and interpreted (Figure 1, green circle).
3. An integrated overview of *nano-specific and general legal regulatory requirements*, the options within which are informed by a series of interlinked decision-making points along the value chain and life cycle of NMs (Figure 1, grey boxes). Regulations evolve with time, and so the framework needs to be able to adapt to changes in the broader regulatory environment.⁽²⁷⁾ Simultaneously, by demonstrating the need and/or ability to deal with NMs of high or unknown risk, the framework can guide development of NM-specific regulations.

1
2
3 We believe that the integration of these three elements has the potential to generate a robust
4 and encompassing risk governance framework for NMs, which fulfills the six criteria outlined
5
6
7 below.

3.2. Criteria for a Promising NM Risk Governance Framework

11 The goal of achieving sustainable development for nanotechnologies – by instilling
12 trust into NM innovation and avoiding piece-meal solutions to risk governance – forms the
13 starting point for our risk governance framework. Criteria for such a NM risk governance
14
15 framework therefore include:

16
17 *The need to fully leverage existing knowledge and tools.* A risk governance framework
18
19 is most likely to further trust in NM innovation when integrating and exploiting the best,
20
21 currently available tools (see Table I). Projects such as caLIBRAte (European Commission
22
23 funded via Horizon 2020) are already working towards the calibration of such tools, and aim
24
25 to collect and analyze existing control banding tools and quantitative hazard, exposure and
26
27 risk assessment models and risk management systems for nanomaterials. Further, these tools
28
29 are selected for sensitivity analysis, performance testing, further improvement and calibration
30
31 with a final aim that the framework and its underlying tools represent the state of the art in
32
33 analytical capacity to inform nanotechnology risk governance decision making.

34
35 *Robust protocols to address incomplete knowledge.* Risk assessment, notably for next
36
37 generation NMs, is likely to be based on incomplete datasets and subject to high uncertainty.
38
39 Therefore, a framework which employs effective strategies to deal with gaps in knowledge is
40
41 required.

42
43 *Ability to adapt to new insights and new NMs.* Given the high velocity of
44
45 developments in the NM field, static frameworks risk falling out of sync quickly. Therefore, a
46
47 framework must be sufficiently adaptable as to allow the included tools to be updated for
48
49 future generations of NMs, and to incorporate learning over time. Such an adaptive style of
50
51 governance should be flexible enough to account for the unique political and institutional
52
53
54
55
56
57
58
59
60

1
2
3 realities of a given jurisdiction, and allow existing regulatory structures to iteratively
4
5 incorporate new risk knowledge over time such as via TSCA in the United States, or REACH
6
7 regulations in the European Union.⁽²⁸⁾
8

9
10 *Comprehensive consideration of the motivation of various users:* For a framework to
11
12 be effective, it has to accommodate the responses of the various parties (e.g., employers,
13
14 workers, regulators, policy makers, insurers, general public) in order to motivate compliance
15
16 and best practices. Motivations can be provided in a variety of forms, e.g., as financial
17
18 incentives, as legal liabilities, socially embedded norms of appropriateness, role models or via
19
20 a corporate code of conduct.
21

22
23 *Communicate the advantages of employing rules and regulations.* For the rules and
24
25 regulations to be effective, their rationale has to be effectively linked to the motivations,
26
27 norms and interests of the various actors. This requires evidence and storylines of how they
28
29 help in protecting workers, society, the environment and consequently the sustainability of
30
31 nano industries.
32

33
34 *Delivering compliance and beyond:* A risk governance framework for NMs seems
35
36 most promising in achieving the objective of sustainable NMs if it not only fosters
37
38 organizational practices which ensure compliance with current and future legal and regulatory
39
40 requirements, but also goes beyond pure compliance and stimulates proactive ‘good’ behavior
41
42 and innovation.
43

44
45 By adopting these objectives the resultant risk governance framework will be
46
47 responsive, rational, transparent and inclusive in the sense that it uses and constantly up-dates
48
49 all available data, links them to decision-making guidance through publicly available rules
50
51 and integrates the needs and concerns of a wide range of stakeholders.
52

53 **3.3. Tools and strategies for assessing potential risk and risk decision making**

54
55 We propose a set of four advanced tools and strategies to support risk decision making: risk
56
57 banding, risk mitigation, risk transfer, and user capacities and needs. The first tool, risk
58
59
60

1
2
3 banding, stems from risk assessment strategies. Risk assessment systematically applies
4
5 scientific principles, guided by the precautionary principle, to estimate the probability that
6
7 adverse human health or environmental effects could emerge from exposure to substances.
8
9 The risk assessment framework is composed of problem formulation, exposure assessment,
10
11 hazard assessment as well as risk and uncertainty characterization.⁽²⁹⁾
12
13

14 The paradigm for risk assessment of chemicals is considered applicable to nanoscale
15
16 materials,^(26,30,31) however many of the tools, test protocols and guidelines for determination
17
18 and assessment of physicochemical properties, fate, exposure, and effects used for
19
20 conventional chemicals need modifications when applied to (the regulatory) safety assessment
21
22 of NMs. The work on adapting existing methods for NMs has been ongoing in the
23
24 Organisation for Economic Co-operation and Development (OECD) Working Party of
25
26 Manufactured Nanomaterials (WPMN) and in many research projects. This work has resulted
27
28 in an array of nano-specific or nano-relevant experimental and modelling tools suited to
29
30 address the complexity associated with the identity, biological and environmental interactions
31
32 of NMs in order to reduce the uncertainty in their risk assessment. These tools were
33
34 comprehensively reviewed by Hristozov et al.⁽³²⁾
35
36
37

38 These tools have been applied to generate extensive physicochemical, hazard and
39
40 exposure datasets. However, while a significant body of data exists for some NMs, for many
41
42 (including next-generation) NMs, risk assessment is likely to be based on incomplete datasets.
43
44 When combined with the significant uncertainty regarding extrapolation from animal or *in*
45
46 *vitro* hazard data to the quantification of human health or environmental risks, this lack of
47
48 data could result in an under-protective or overly conservative assessment of health risks,
49
50 resulting in either unacceptable risks or stifled innovation. Given the fast development of
51
52 highly innovative NMs, it is not feasible to complete a risk assessment of NMs on a case-by-
53
54 case basis. Hence, new approaches to risk assessment are required⁽³³⁾ which allow for
55
56
57
58
59
60

1
2
3 accelerating the risk assessment process, for example via grouping and/or read-across of
4
5 NMs.
6

7 Bodies such as the OECD and ECHA⁽³⁴⁻³⁶⁾ are developing NM grouping or
8
9 categorization schemes⁽³⁷⁾ in order to reduce the extensive hazard, exposure and
10
11 physicochemical testing requirements to a feasible level. A number of studies have been
12
13 developing risk banding tools (e.g., Stoffenmanager Nano,⁽³⁸⁾ NanoRiskCat,⁽³⁹⁾ Swiss
14
15 Precautionary Matrix, NanoSafer etc), which are based on the Precautionary Principle and are
16
17 designed to incorporate the full range of uncertainty in their results in order to inform risk
18
19 management decisions based on worst-case scenarios.⁽⁴⁰⁾ In a differing approach, the US
20
21 FDA, among other agencies, convene quarterly interest groups which review risk and
22
23 regulatory concerns of emerging trends in NM development, including risk categorization
24
25 exercises and product-specific regulatory discussion.^(21,22) Moreover, risk screening and
26
27 ranking schemes based on weight of evidence approaches have been proposed, which
28
29 explicitly estimated the uncertainty stemming from hazard and exposure assessments.
30
31 Specifically, Hristozov et al.⁽⁴¹⁾ developed the first quantitative Multi-Criteria Decision
32
33 Analysis (MCDA) methodology for human health hazard identification of NMs, which
34
35 incorporated data quality evaluation of the available dataset, based on the criteria adequacy,
36
37 reliability, statistical and toxicological significance.⁽⁴²⁾ Moreover, a quantitative MCDA
38
39 approach for prioritization of nano-specific exposure scenarios was proposed for occupational
40
41 settings,⁽⁴³⁾ and a quantitative MCDA methodology for human health risk ranking of NMs
42
43 was developed.⁽⁴⁴⁾ All three approaches quantified the uncertainty in the assessments by
44
45 means of a Monte Carlo methodology.
46
47
48
49
50

51
52 If successful, such grouping and categorization schemes provide the opportunity to fill
53
54 missing data within groups of similar NMs using computational (*in silico*) techniques such as
55
56 Quantitative Structure Activity Relationships for NMs (abbreviated as: nano-QSAR, QNAR,
57
58 QNTR)⁽⁴⁵⁻⁴⁷⁾ or read-across between NMs, or between NMs and other substances.⁽⁴⁷⁾ As a
59
60

1
2
3 result, time and cost of testing as well as the use of laboratory animals could be reduced. In
4
5 fact, great progress in developing *in silico* methods for risk assessment of NMs has been made
6
7 by several EU FP7 “modelling projects” (NanoPUZZLES, MODERN, ModENPTox,
8
9 MembraneNanoPart, PreNanoTox). These projects have jointly proposed criteria important
10
11 for appropriate quality validation of nano-QSAR models to be developed in future
12
13 initiatives.⁽⁴⁸⁾

16 For such risk assessment tools to be effective they will require a combination of
17
18 analytical, computational toxicology, machine learning and Bayesian methods to unravel and
19
20 clearly communicate the uncertainties in the results. The risk assessment tool will need to
21
22 provide information that is applicable to occupational, consumer and environmental settings,
23
24 addressing different life cycle stages of the NMs in order to address risks from the design and
25
26 manufacture stages through to disposal and recycling. The risk assessment tool should take
27
28 into account the level of human and environmental exposure and be sufficiently flexible to
29
30 accommodate new and future generations of NMs, even when the available data on hazard,
31
32 exposure and physicochemical characteristics is scarce or even lacking (perhaps by using
33
34 expert judgment and weight of evidence methodology in a transparent manner). Any risk
35
36 assessment tool will need to push beyond the state-of-the-art by addressing the uncharted
37
38 issues of uncertainty related to NM risks. This is relevant for consideration of human health
39
40 and environmental impact of NMs including susceptible group(s) in the general population
41
42 and susceptible species in the environment, as well as the impact of NM accumulation in
43
44 environmental hot spots. It also includes consideration of human behavioral uncertainties
45
46 based on diverging risk perceptions, organizational routines, and social norms.

51
52 To allow for effective risk management of NMs, the risk assessment tool could be
53
54 linked with tools for risk mitigation and risk transfer. A range of practical NM risk mitigation
55
56 strategies are required to reduce or prevent risks posed by NMs. These include technical risk
57
58 mitigation approaches (e.g., safer-by-design), safer manufacturing processes, safer handling
59
60

1
2
3 procedures, and improved exposure controls (e.g., high-efficiency filters). Currently,
4
5 mitigation approaches, including methods and tools, have been or are being developed in EU
6
7 FP7 funded projects such as SUN, SANOWORK, NANOMICEX, NANOVALID and
8
9 GUIDEnano. Safer-by-design approaches are also the main research topics of NANoREG II
10
11 and ProSAFE. Other initiatives to prevent or minimize risk include the development and
12
13 application of the precautionary principle, as well as soft law initiatives to drive consideration
14
15 of nanomaterial-derived product liability and insurance.^(49,50) Tools designed to apply the
16
17 precautionary principle are mostly inspired by the selection of appropriate levels of
18
19 engineering controls (e.g., engineering techniques and personal protective equipment)⁽⁴⁶⁾ or
20
21 green safer product design or process optimization (e.g., NIOSH's prevention through design
22
23 initiative).⁽⁵¹⁾
24
25
26

27 Risk mitigation strategies also include management support tools (e.g., technical
28
29 training materials for stakeholders) designed to promote adherence to health and safety
30
31 policies. Development of such tools could result in improved strategic and transparent
32
33 identification of approaches to mitigate human and environmental risks associated with NMs.
34
35

36 A governance framework has to provide guidance for the options for a relevant
37
38 selection of mitigation measures especially in relation to their effectiveness and the value or
39
40 quality of information about their effectiveness. Together with the definition of technical
41
42 indicators (which quantify conditions in which measures success or failure) this could also
43
44 facilitate the risk transfer by impacting on the reduction of risk premiums by insurance
45
46 companies (see below).
47
48

49 The available options for risk transfer frame the risk management process in relation
50
51 to factors such as non-contractual and contractual liabilities (see below), (re)insurability of
52
53 risks, and the ensuing distribution of legal and financial risks that influence decision making.
54
55 Currently, there is no systematic approach to qualify and quantify NM risk with regard to
56
57 insurance. At present, insurers implicitly assume nano-specific risk in their health-related or
58
59
60

1
2
3 general-purpose insurance policies,^(52,53) an approach they are uncomfortable with but do not
4
5 have the knowledge to exclude in a competitive business. To achieve reliable risk transfer
6
7 arrangements, tools and associated guidance are required that allow mathematical
8
9 quantification of risks and risk categorization in a context of uncertainty. In addition, tools are
10
11 needed that identify or develop legally reliable arrangements (see below) between relevant
12
13 parties involved in the life cycle and value chains relevant to NMs.
14
15

16
17 In order for the risk assessment, mitigation and transfer tools to guide effective risk
18
19 management and risk decision making, their activities and outputs need to be integrated. This
20
21 can be achieved through development and use of a decision support system (DSS). Prototype
22
23 risk assessment and DSSs for NM risk management have been developed in FP7 funded
24
25 projects such as SUN and GUIDEnano. These tools are in their early stages of development,
26
27 and are based on the exploitation of a relatively small number of NM product case studies.
28
29 Hence, a substantial body of work is required to enhance their reliability and suitability for
30
31 wider arrays of NMs and NM products (across their value chain/life cycle), exposure
32
33 scenarios and for a broader set of stakeholders. To improve DSSs further, it will be useful in
34
35 the future to integrate the risk management tools with a tool to assess the needs, values and
36
37 capacities of a wide range of users. The design of such a DSS allows the individual tools to be
38
39 modified and advanced as each is improved, thereby ensuring that it remains up to date and
40
41 relevant. Achievement of such a DSS optimally increases the efficiency of the risk
42
43 governance process, for example by reducing the requirement for testing, and assists
44
45 stakeholders with practical guidance in their decision making process for NMs throughout the
46
47 value chain and life cycle.
48
49
50

51
52 For the governance framework to be useful for stakeholders it is essential that the
53
54 outputs can be adjusted to meet the needs of the user and to provide a level of detail that is
55
56 relevant to their understanding and expertise.⁽⁵⁴⁾ Assessment of user capacities (e.g.,
57
58 experience and relevant knowledge) allows consideration of different types and levels of
59
60

1
2
3 expertise (e.g., a ‘coal face’ worker never involved in risk assessment compared to an
4 experienced occupational health professional).⁽⁵⁵⁾ According to this type of analysis the
5 framework and tools can be adapted to provide outputs that better suit the requirements and
6 understanding of different types of users.
7
8
9

10
11 Finally, the DSS outputs need to integrate stakeholder values with evidence-based
12 input in order to recommend clear actions for decision makers. Practical and clear advice for
13 regulatory compliance and best practice should be provided (see below). Integration of these
14 tools allows a national, international and potentially globally applicable standard for the
15 governance of current and future NMs and their applications to be identified.
16
17
18
19
20
21

22 **3.4. Human behavior and decision making**

23
24 Human behavior and how individuals or organizations prepare and take decisions can vary
25 considerably. Variability in decision making is driven via a wide array of factors including the
26 social context in which the decision is made (e.g., domestic vs. occupational settings), the
27 perception of risks versus potential benefits, the individual or organizational routines and
28 heuristics (i.e. using decisional shortcuts with potential for error).^(56,57) These factors apply
29 whether the decision is made by an individual or a team, and whether it is made to align with
30 specific regulations, guidelines or ethical considerations.
31
32
33
34
35
36
37
38
39

40
41 To generate an effective governance framework, there is a need to identify the
42 individual, organizational and societal determinants of decision making about NM risk
43 management and transfer along the full value chain and life cycle of NMs. While generic
44 analytical frameworks are available to identify such determinants (e.g., the *homo*
45 *oeconomicus institutionalis* framework⁽⁵⁸⁾), determinants are expected to vary across different
46 types of contexts. Hence inputs from stakeholders and the wider public are needed to identify
47 how user concerns and needs depend on the types of decisions (e.g., NM design, which NM to
48 use, how to dispose of a NM) and the type of contexts (e.g., research laboratory, factory, or in
49 a regulatory capacity). Building on such context-specific insights will allow for developing
50
51
52
53
54
55
56
57
58
59
60

1
2
3 differentiated risk communication strategies, which need to be dialogical (two-way), to enable
4
5 co-learning and to enhance trust in the governance of risks from NMs.
6

7 **4. IMPLEMENTATION OF THE RISK GOVERNANCE FRAMEWORK**

8
9 Before such a framework can be delivered the individual tools need to be generated and
10
11 validated. The tool development will need to be evidence-based taking into account the norms
12
13 and motivations of the users and the impediments to be addressed by the governance
14
15 framework. The tools need to be built on existing achievements of on-going or completed
16
17 national or international projects, going beyond the state-of-the-art by systematically
18
19 diagnosing user needs and capacities, integrating likely behavior, dynamic links to developing
20
21 knowledge about NM risks, integration of uncertainty into risk assessment. Importantly, to
22
23 achieve this they need to undergo interactive testing in practice.⁽⁵⁹⁾ Empirical studies will
24
25 therefore be required to illustrate how the tools and guidance of the framework function in a
26
27 comprehensive and relevant range of practice contexts, and to verify its reliability. Case
28
29 studies which do not focus on various NMs in isolation, but rather a range of NMs along their
30
31 respective value chains and life cycles, including interactions with people in different settings
32
33 (e.g., in industries, as regulators, as researchers, as consumers and in the environment), seem
34
35 a promising way to gain these insights. Such case studies would need to include a breadth of
36
37 natural and social science data. Ideally, each case study would demonstrate how an open
38
39 society addresses the issue of emerging technology and its possible inherent risks in a
40
41 responsible manner. This will include arrangements for the transfer of risks and the steps
42
43 required by insurers before underwriting any risks. It will also include signposts for
44
45 communicating the risks, in creating a narrative that informs and involves the stakeholders in
46
47 making the key governance decisions to help nurture and sustain the nano industries in a
48
49 socially desirable manner.
50
51
52
53
54

55
56 We believe that an international strategy to build such a governance framework is
57
58 necessary in order to ensure that the framework is sufficiently adaptable to allow and
59
60

1
2
3 encourage improved national, international and global harmonization as well as sustain and
4
5 likely expand the global market for nanotechnology. Such a framework needs also to
6
7 empower the broad range of stakeholders in nanotechnology governance with tools that
8
9 improve practical decision-making in a governance framework that is perceived by society as
10
11 fair, trustworthy and effective. Furthermore it provides a vehicle to share and organize
12
13 information, thereby improving the efficiency of risk decision-making.⁽⁶⁰⁾
14
15

16 5. FUTURE STEPS

17
18 With this article, we would like to call for an international strategy to develop an integrated
19
20 risk governance framework for NMs. This would enable a cooperative and international
21
22 approach to the governance of NM-related risks through the systematic consideration and
23
24 integration of stakeholder and user needs, dynamic risk assessment tools and consideration of
25
26 the various regulatory requirements in multi-layered and fragmented regulatory environments.
27
28 For rendering such an effort successful, the essential elements of the framework need to be
29
30 delivered and integrated effectively. The outlined strategy will support stakeholders with
31
32 diverse backgrounds and knowledge requirements, essentially providing a ‘user paradigm’
33
34 consisting of practical advice and solutions for existing and innovative NMs entering the
35
36 market. Continued involvement of all relevant stakeholders throughout the construction of the
37
38 framework will be essential. This *inclusive* approach guarantees the maximal stakeholder
39
40 involvement through construction, consultation, and revision phases. Furthermore, the
41
42 strategy involves the stakeholders in the design, testing and implementation of the framework
43
44 and this process of co-production thereby safeguards its relevance and *transparency* leading
45
46 to enhanced potential for *trust*.⁽⁶¹⁾
47
48
49
50

51
52 In achieving this risk governance strategy, new solutions will be provided to evaluate
53
54 the risks potentially arising from the use of NMs, including future NMs. In this regard, the
55
56 governance framework will likely have significant impact on nanotechnology industries and
57
58 for investors in nanotechnology, supporting SMEs and large companies in the selection of
59
60

1
2
3 safer products and processes, limiting the potential adverse effects of NMs on workers and
4
5 consumers, and reducing insurance costs and risks to public budgets derived from any
6
7 potential future major accidents or diseases.⁽⁶²⁾
8

9
10 By enabling the emergence of reliable expectations about the behaviors and decisions
11
12 along the value chain, the governance framework proposed here would be attractive for key
13
14 stakeholders, including the insurance industry which underwrites the risks of these
15
16 technologies, and the financial industry which invests in it. It would facilitate coordinated risk
17
18 assessment, management and communication across diverging regulatory environments.
19
20 Achievement of such a governance framework will help to realize informed, effective,
21
22 responsive and proportionate governance of NM risks for humans and the environment. It is
23
24 thus a cornerstone for optimizing social and economic benefits of nanotechnology.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. The Royal Society and Royal Academy of Engineers. Nanoscience and nanotechnologies: Opportunities and uncertainty, 2004,
https://royalsociety.org/~media/Royal_Society_Content/policy/publications/2004/9693.pdf
2. Linkov I, Satterstrom FK, Monica JC, Foss S. Nano risk governance: Current developments and future perspectives. *Nanotechnology Law & Business*, 2009; 6: 203-220.
3. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on the appropriateness of the risk assessment methodology in accordance with the technical guidance documents for new and existing substances for assessing the risk of nanomaterials. European Commission, Brussels, 2007,
http://ec.europa.eu/health/ph_risk/committees/04_cbugr/docs/scenihr_o_004c.pdf
4. European Food Safety Authority (EFSA). Scientific opinion: Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. *EFSA Journal*, 2011; 9: 2140.
5. Bevir M, Rhodes RAW, Weller P. Traditions of governance: Interpreting the changing role of the public sector. *Public Administration*, 2003: 81, 1-17.
6. Jahnle J. Conceptual questions and challenges associated with the traditional risk assessment paradigm for nanomaterials. *Nanoethics*, 2015; 9: 61–276.
7. Ostrom E. Beyond markets and states: Polycentric governance of complex economic systems. *American Economic Review*, 2010; 100: 641-672.
8. Justo-Hanani R, Dayan T. European risk governance of nanotechnology: Explaining the emerging regulatory policy. *Research Policy*, 2015; 44: 1527-1536.

- 1
2
3 9. Palma-Oliveira JM, Trump BD, Wood MD, Linkov I. Community-driven hypothesis
4 testing: A solution for the tragedy of the anticommons. Risk Analysis, 2017:
5
6 10.1111/risa.12860.
7
8
- 9
10 10. Purnhagen K, Feindt PF. Making responsive behavioural regulation work in the new
11 better regulation strategy. European Journal of Risk Regulation, 2015; 6: 361-368.
12
- 13 11. [https://www.nanosafetycluster.eu/news/217/66/NanoSafety-Cluster-Research-Regulatory-](https://www.nanosafetycluster.eu/news/217/66/NanoSafety-Cluster-Research-Regulatory-Roadmap-2017.html)
14 [Roadmap-2017.html](https://www.nanosafetycluster.eu/news/217/66/NanoSafety-Cluster-Research-Regulatory-Roadmap-2017.html)
15
- 16 12. Van der Meulen B, Bremmers H, Purnhagen K, Gupta N, Bouwmeester H, Geyer LL.
17
18 Governing Nano Foods: Principles-Based Responsive Regulation. Cambridge: Academic
19 Press, 2014.
20
21
- 22 13. Mohan M, Trump BD, Bates ME, Monica JC, Linkov I. Integrating legal liabilities in
23 nanomanufacturing risk management. Environmental Science & Technology, 2012; 46:
24 7955-7962.
25
26
- 27 14. Malloy T, Trump BD, Linkov I. Risk-based and prevention-based governance for
28 emerging materials. Environmental Science & Technology, 2016; 50: 6822-6824.
29
30
- 31 15. http://ec.europa.eu/environment/chemicals/reach/review_2012_en.htm
32
33
- 34 16. Aitken R, Hankin S, Peters S, Bassan A, Friedrichs S, Foss Hansen S, et al. Specific
35 advice on exposure assessment and hazard/risk characterisation for nanomaterials under
36 REACH (RIP-oN3), 2011.
37
38
- 39 17. Hankin SM, Peters SAK, Poland CA, Foss Hansen S, Holmqvist J, Ross BL, et al.
40 Specific Advice on Fulfilling Information Requirements for Nanomaterials under REACH
41 (RIP-oN 2) - Final Project Report, 2011.
42
43
- 44 18. Communication from the commission to the European Parliament, the Council and the
45 European Economic and Social Committee second regulatory review on nanomaterials,
46 COM/2012/0572 final.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 19. Commission Recommendation 2011/696/EU of 18 October 2011 on the definition of
4 nanomaterial. OJ L 275: 38-41.
5
6
7 20. Krug HF. Nanosafety research: Are we on the right track? *Angewandte Chemie*
8
9 *International Edition*, 2014; 53: 12304-12319.
10
11 21. Bawa R. FDA and nano: Baby steps, regulatory uncertainty and the bumpy road ahead. In
12 *Handbook of clinical nanomedicine: Law, business, regulation, safety, and risk* (pp. 339-
13 383). Pan Stanford, 2016.
14
15 22. Miettinen, M. (2016). Comparison of the approaches to regulate environmental, health,
16 and safety risks of nanomaterials in the chemicals, food, and pesticides/biocides sectors in
17 the EU and the US. University of Eastern Finland, 2016.
18
19 23. Renn O, Roco MC. Nanotechnology and the need for risk governance. *Journal of*
20 *Nanoparticle Research*, 2006; 8: 153-191.
21
22 24. Seager TP, Trump BD, Poinsette-Jones K, Linkov I. Why life cycle assessment does not
23 work for synthetic biology. *Environmental Science & Technology*, 2017:
24 10.1021/acs.est.7b01604
25
26 25. Linkov I, Trump BD, Wender BA, Seager TP, Kennedy AJ, Keisler JM. Integrate life-
27 cycle assessment and risk analysis results, not methods. *Nature Nanotechnology*, 2017:
28 12, 740.
29
30 26. Stone, V., Pozzi-Mucelli, S., Tran, L., Aschberger, K., Sabella, S., Vogel, U., Poland, C.,
31 Balharry, D., Fernandes, T.,Gottardo, S.,Hankin, S.,Hartl,M.G.J., Hartmann,N.,Hristozov,
32 D., Hund-Rinke, K., Johnston, H., Marcomini, A., Panzer, O., Roncato, D., Saber, A.T.,
33 Wallin, H., Scott-Fordsmand, J.J., 2014. ITS-NANO—Prioritising nanosafety research to
34 develop a stakeholder driven intelligent testing strategy. Part. *Fibre Toxicol.* 11.
35
36 27. Trump BD. Synthetic biology regulation and governance: Lessons from TAPIC for the
37 United States, European Union, and Singapore. *Health Policy*, 2017:
38 10.1016/j.healthpol.2017.07.010
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28. Trump B, Cummings C, Kuzma J, Linkov I. A decision analytic model to guide early
4 stage government regulatory action: Applications for synthetic biology. *Regulation &*
5 *Governance*, 2017: DOI: 10.1111/rego.12142
6
7
8
9
10 29. Van Leeuwen, C., Vermeire, T., 2007. *Risk Assessment of Chemicals: An Introduction*.
11 Springer, Dordrecht.
12
13
14 30. EFSA, 2010. *Opinion on the Potential Risks Arising from Nanoscience and*
15 *Nanotechnologies on Food and Feed Safety*. European Food Safety Authority, Brussels.
16
17
18 31. OECD and European Commission, 2012. *Series on the Safety of Manufactured*
19 *Nanomaterials No. 33: Important Issues on Risk Assessment of Manufactured*
20 *Nanomaterials*. Paris.
21
22
23
24
25 32. Hristozov D, Gottardo S, Semenzin E, Oomen A, Bos P, Peijnenburg W, Van Tongeren
26 M, Nowack B, Hunt N, Brunelli A, Scott-Fordsmand JJ. Frameworks and tools for risk
27 assessment of manufactured nanomaterials. *Environ International*, 2016; 95: 36-53.
28
29
30
31 33. Stone V, Nowack B, Baun A, Van den Brink N, Von der Kammer FA, Dusinska M, et al.
32 *Nanomaterials for environmental studies: Classification, reference material issues, and*
33 *strategies for physico-chemical characterisation*. *Science of the Total Environment*, 2009;
34 408: 1745-1754.
35
36
37
38
39
40 34. ECHA. *Assessing human health and environmental hazards of nanomaterials - Best*
41 *practice for REACH registrants*; 2013 21-22 January 2013.
42
43
44
45 35. ECHA. *Human health and environmental exposure assessment and risk characterisation of*
46 *nanomaterials - Best practice for REACH registrants*; 2014 30 September 2013.
47
48
49 36. Arts JH, Hadi M, Irfan MA, Keene AM, Kreiling R, Lyon D, et al. A decision-making
50 framework for the grouping and testing of nanomaterials (DF4nanoGrouping). *Regulatory*
51 *Toxicology and Pharmacology*, 2015; 71: S1-S27.
52
53
54
55
56
57
58
59
60

- 1
2
3 37. Godwin H, Nameth C, Avery D, Bergeson LL, Bernard D, Beryt E, et al. Nanomaterial
4 categorization for assessing risk potential to facilitate regulatory decision-making. ACS
5 Nano, 2015; 9: 3409-3417.
6
7
8
9
10 38. Stoffenmanager Nano. 2015, Available from: <https://nano.stoffenmanager.nl/>
11
12 39. NanoRiskCat., Available from: <http://www2.mst.dk/udgiv/publications/2011/12/978-87-92779-11-3.pdf>
13
14
15
16 40. Scott-Fordsmand JJ, Pozzi-Mucelli S, Tran L, Aschberger K, Sabella S, Vogel U, et al. A
17 unified framework for nanosafety is needed. Nano Today, 2014; 9: 546-549.
18
19
20 41. Hristozov D, Zabeo A, Foran C, Isigonis P, Critto A, Marcomini A, Linkov I. A weight of
21 evidence approach for hazard screening of engineered nanomaterials. Nanotoxicology,
22 2014; 8: 72-87.
23
24
25
26
27 42. Linkov I, Bates ME, Trump BD, Seager TP, Chappell MA, Keisler JM. For
28 nanotechnology decisions, use decision analysis. Nano Today, 2013; 8, 5-10.
29
30
31
32 43. Hristozov D, Gottardo S, Cinelli M, Isigonis P, Zabeo A, Critto A, Van Tongeren M, Tran
33 L, Marcomini A. Application of a quantitative weight of evidence approach for ranking
34 and prioritizing occupational exposure scenarios for titanium dioxide and carbon
35 nanomaterials. Nanotoxicology, 2014; 8: 117-131.
36
37
38
39
40 44. Hristozov D, Zabeo A, Jensen KA, Gottardo S, Isigonis P, Maccalman L, Critto A,
41 Marcomini A, Demonstration of a modelling-based multi-criteria decision analysis
42 procedure for prioritization of occupational risks from manufactured nanomaterials.
43 Nanotoxicology, 2016; 10: 1215-1228.
44
45
46
47
48
49 45. Kleandrova VV, Luan F, González-Díaz H, Ruso JM, Speck-Planche A, Cordeiro MNDS.
50 Computational tool for risk assessment of nanomaterials: Novel QSTR-perturbation
51 model for simultaneous prediction of ecotoxicity and cytotoxicity of uncoated and coated
52 nanoparticles under multiple experimental conditions. Environmental Science and
53 Technology, 2014; 48: 14686-14694.
54
55
56
57
58
59
60

- 1
2
3 46. Puzyn T, Rasulev B, Gajewicz A, Hu X, Dasari TP, Michalkova A, et al. Using nano-
4
5 QSAR to predict the cytotoxicity of metal oxide nanoparticles. *Nature Nanotechnology*,
6
7 2011; 6: 175-178.
8
9
10 47. Gajewicz A, Cronin MTD, Rasulev B, Leszczynski J, Puzyn T. Novel approach for
11
12 efficient predictions properties of large pool of nanomaterials based on limited set of
13
14 species: Nano-read-across. *Nanotechnology*, 2015; 26: 015701.
15
16
17 48. Puzyn T, Jeliaskova N, Sarimveis H, Robinson RM, Lobaskin V, Rallo R, et al. On the
18
19 validation of criteria of (A)SAR models used in nanotechnology. Submitted.
20
21 49. Stebbing M. Avoiding the trust deficit: Public engagement, values, the precautionary
22
23 principle and the future of nanotechnology. *Journal of Bioethical Inquiry*, 2009; 6: 37-48.
24
25
26 50. Marchant GE. 'Soft Law' mechanisms for nanotechnology: Liability and insurance
27
28 drivers. *Journal of Risk Research*, 2014; 17, 709-719.
29
30 51. Murashov V, Howard J. Essential features for proactive risk management. *Nature*
31
32 *Nanotechnology*, 2009; 4: 467-470.
33
34 52. Mullins M, Murphy F, Baublyte L, McAlea EM, Tofail SAM. The insurability of
35
36 nanomaterial production risk. *Nature Nanotechnology*, 2013; 8: 222-224.
37
38 53. Murphy F, Mullins M, Hester K, Gelwick A, Scott-Fordsmand JJ, Maynard T. Insuring
39
40 nanotech requires effective risk communication. *Nature Nanotechnology*, 2017: 12, 717-
41
42 719.
43
44
45 54. Pidgeon N, Harthorn B, Satterfield T. Nanotechnology risk perceptions and
46
47 communication: Emerging technologies, emerging challenges. *Risk Analysis*, 2011; 31:
48
49 1694-1700.
50
51
52 55. Scheufele DA, Corley EA, Dunwoody S, Shih TJ, Hillback E, Guston DH. Scientists
53
54 worry about some risks more than the public. *Nature Nanotechnology*, 2007; 2: 732-734.
55
56
57 56. Thaler RH, Sunstein CR, Balz JP. Choice architecture. The behavioral foundations of
58
59 public policy, 2013: 428-439.
60

- 1
2
3 57. Bates ME, Grieger KD, Trump BD, Keisler JM, Plourde KJ, Linkov I. Emerging
4 technologies for environmental remediation: Integrating data and judgment.
5 Environmental Science & Technology, 2015: 50, 349-358.
6
7
8
9
10 58. Führ M, Bizer K. REACh as a paradigm shift in chemical policy - responsive regulation
11 and behavioural models. Journal of Cleaner Production, 2007; 5: 327-334.
12
13
14 59. Read SA, Kass GS, Sutcliffe HR, Hankin SM. Foresight study on the risk governance of
15 new technologies: The case of nanotechnology. Risk Analysis, 2016; 36: 1006-1024.
16
17
18 60. Shatkin JA, Ong KJ, Beaudrie C, Clippinger AJ, Hendren CO, Haber LT, et al. Advancing
19 risk analysis for nanoscale materials: Report from an international workshop on the role of
20 alternative testing strategies for advancement. Risk Analysis, 2016; 36: 1520-1537.
21
22
23
24 61. Poortvliet PM, Lokhorst AM. The key role of experiential uncertainty when dealing with
25 risks: Its relationships with demand for regulation and institutional trust. Risk Analysis,
26 2016; 36: 1615-1629.
27
28
29
30
31 62. Blaunstein R, Trump BD, Linkov I. Nanotechnology risk management: An insurance
32 industry perspective. Nanotechnology Environmental Health and Safety. Risks,
33 Regulation, and Management, 2014. 247-263.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table I.*Definitions for risk management tools*

Tool	Definition
Risk banding	Allows risk assessment to be performed with incomplete hazard, exposure and physicochemical characterization
Risk mitigation	Provides advice on technical interventions that can reduce the risk and supports worker/decision-making training
Risk transfer	Enables consideration of legal, contractual and insurance arrangements to be made in the decision-making process
User needs and capacities	Assesses expertise and experience of user to determine the format of the information required and the level of detail

Figure 1.

Essential elements for a risk governance framework for nanomaterials. The central circle houses tools that feed into a decision support system. The decisions generated are guided by the legal/regulatory frameworks (grey boxes), which are determined and interpreted by humans in real life situations (green circle).



ew